Overview

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)

Status:
Completed
Trial end date:
2016-01-20
Target enrollment:
Participant gender:
Summary
The study purpose is to assess the impact of an educational program on patient adherence in patients taking Apixaban for SPAF at 24 weeks
Phase:
Phase 4
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Apixaban